Screener
Edgewise Therapeutics, Inc. EWTX Business Segments — Other Nonoperating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.
The source filing: Edgewise Therapeutics, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 8:05 AM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020112
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Loss from operations | (191,406) | (158,832) | (114,357) |
| Other income | |||
| Interest income | 23,611 | 25,019 | 14,194 |
| Total other income | 23,611 | 25,019 | 14,194 |
| Net loss | (167,795) | (133,813) | (100,163) |
| Other comprehensive income (loss): | |||
| Unrealized gain on available-for-sale securities | 257 | 321 | 1,454 |
| Total comprehensive loss | $(167,538) | $(133,492) | $(98,709) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Edgewise Therapeutics, Inc.'s business segments — other nonoperating income?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — other nonoperating income of $5.9M in Q4 2025.
- How has Edgewise Therapeutics, Inc.'s business segments — other nonoperating income changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — other nonoperating income decreased by 5.6% year-over-year, from $6.25M to $5.9M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — other nonoperating income?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — other nonoperating income has grown at a 29.0% compound annual growth rate (CAGR), from $14.19M to $23.61M.
- What does business segments — other nonoperating income mean?
- Includes income generated from activities outside of the company's primary business operations, such as asset sales or miscellaneous financial gains. This metric highlights secondary sources of cash flow that supplement the core business. It is useful for identifying one-time gains that may distort the underlying operational performance.
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — other nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude